Accelerated Pharma Announces Expected Price Range for IPO

By Chris Lange Updated Jan 13, 2:31AM EST · Published Oct 12, 7:45AM EDT

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Accelerated Pharma Announces Expected Price Range for IPO — © Thinkstock

Accelerated Pharma has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). The company intends to price its 1.89 million shares in the range of $8 to $10, with an overallotment option for an additional 283,334 shares. At the maximum price, the entire offering is valued up to $21.72 million. The company intends to list its shares on the Nasdaq under the symbol ACCP.

The underwriters for the offering are Rodman & Renshaw and Maxim Group.

This clinical stage biopharmaceutical company is focused on utilizing its genomic technology to enhance the development of pre-existing pharmaceutical products for the treatment of various cancer indications, prospectively identify patients that may respond to such pharmaceutical products and commercialize such pharmaceutical products for sale in various markets.

The lead product candidate is Picoplatin, a new generation platinum-based cancer therapy that has the potential for use in different formulations, as a single agent or in combination with other anti-cancer agents, to treat multiple cancer indications. Accelerated Pharma holds and are the exclusive, worldwide licensee of patented and proprietary technology related to Picoplatin.

[nativounit]

The company initially will use its genomic technology to identify suitable patients prospectively for its anticipated Picoplatin clinical trials in hope of obtaining regulatory approval for Picoplatin and commercializing the therapy. Ultimately, the company believes that its genomic program will allow it to identify additional drug candidates that can be substantially improved for the treatment of various cancer indications and ultimately create a targeted, driven approach for cancer treatment by selecting patients who will respond to therapy in advance of administering such therapy.

In the filing the company said:

We intend to conduct Phase II clinical trials both in colorectal cancer (or CRC) and squamous cell cancer of the head-and-neck over the next 24 months commencing in November 2016 in order to determine the genomic signatures for Picoplatin with respect to these indications. In October 2016, following its review of our Investigational New Drug Application (or IND) for squamous cell cancer of the head and neck, the FDA gave us permission to initiate Phase II trials of Picoplatin in patients with squamous cell carcinoma of the head and neck.

Accelerated Pharma intends to use the net proceeds from this offering to fund its Phase 2 clinical trial and potentially Phase 3 trials. The remainder of proceeds will be used for working capital and general corporate purposes.

[wallst_email_signup]

About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.